Henry H Y Tong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8467870/publications.pdf

Version: 2024-02-01

257101 189595 2,863 51 24 50 h-index citations g-index papers 51 51 51 3570 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Phase solubility diagrams and energy surface calculations support the solubility enhancement with low hygroscopicity of Bergenin: 4-Aminobenzamide (1: 1) cocrystal. International Journal of Pharmaceutics, 2021, 601, 120537.	2.6	17
2	In Vitro Release Study of the Polymeric Drug Nanoparticles: Development and Validation of a Novel Method. Pharmaceutics, 2020, 12, 732.	2.0	116
3	Effects of the Glass-Forming Ability and Annealing Conditions on Cocrystallization Behaviors via Rapid Solvent Removal: A Case Study of Voriconazole. Pharmaceutics, 2020, 12, 1209.	2.0	10
4	A noninvasive precise treatment strategy for implant-related infections based on X-ray-induced luminescent/photodynamic therapeutic multilayered device surface materials. Journal of Luminescence, 2020, 222, 117108.	1.5	3
5	Extended Release of Highly Water Soluble Isoniazid Attained through Cocrystallization with Curcumin. Crystal Growth and Design, 2020, 20, 1951-1960.	1.4	35
6	Integrated Continuous Plug-Flow Crystallization and Spray Drying of Pharmaceuticals for Dry Powder Inhalation. Industrial & Engineering Chemistry Research, 2019, 58, 16843-16857.	1.8	17
7	X-Ray Diffraction and Theoretical Calculation–Supported Formation of Polymorphic Cocrystals Discovered Through Thermal Methods: A Case Study. Journal of Pharmaceutical Sciences, 2019, 108, 3340-3347.	1.6	19
8	Structure determination and in vitro/vivo study on carbamazepine-naringenin (1:1) cocrystal. Journal of Drug Delivery Science and Technology, 2019, 54, 101244.	1.4	12
9	Comparison of normal versus imiquimod-induced psoriatic skin in mice for penetration of drugs and nanoparticles. International Journal of Nanomedicine, 2018, Volume 13, 5625-5635.	3.3	26
10	Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment. Paediatric Drugs, 2017, 19, 235-250.	1.3	21
11	Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel. Journal of Controlled Release, 2017, 254, 44-54.	4.8	129
12	Topical Fish Oil Application Coupling with Therapeutic Ultrasound Improves Tendon Healing. Ultrasound in Medicine and Biology, 2016, 42, 2983-2989.	0.7	3
13	Resveratrol cocrystals with enhanced solubility and tabletability. International Journal of Pharmaceutics, 2016, 509, 391-399.	2.6	87
14	Evaluation in vitro and in vivo of curcumin-loaded mPEG-PLA/TPGS mixed micelles for oral administration. Colloids and Surfaces B: Biointerfaces, 2016, 141, 345-354.	2.5	71
15	Identification of New Cocrystal Systems with Stoichiometric Diversity of Salicylic Acid Using Thermal Methods. Pharmaceutical Research, 2016, 33, 1030-1039.	1.7	57
16	Synthesis, characterization and thermal analysis of ursolic acid solid forms. Crystal Research and Technology, 2015, 50, 538-548.	0.6	11
17	Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: A systematic review and meta-analysis of observational studies. Neuroscience and Biobehavioral Reviews, 2015, 49, 82-89.	2.9	117
18	In silico prediction of prostaglandin D2 synthase inhibitors from herbal constituents for the treatment of hair loss. Journal of Ethnopharmacology, 2015, 175, 470-480.	2.0	32

#	Article	IF	CITATIONS
19	Application of Nano- and Micro-Particles on the Topical Therapy of Skin-Related Immune Disorders. Current Pharmaceutical Design, 2015, 21, 2643-2667.	0.9	14
20	Quality of online information about sexually transmitted diseases. Online Information Review, 2014, 38, 650-660.	2.2	5
21	Synthesis, crystal structures and phase transformation of the new solid-state forms of tetrandrine. RSC Advances, 2014, 4, 62586-62593.	1.7	22
22	In silico prediction of tyrosinase and adenylyl cyclase inhibitors from natural compounds. Natural Product Communications, 2014, 9, 189-94.	0.2	7
23	In Silico Prediction of the Cosmetic Whitening Effects of Naturally Occurring Lead Compounds. Natural Product Communications, 2012, 7, 1934578X1200701.	0.2	7
24	In silico prediction of the cosmetic whitening effects of naturally occurring lead compounds. Natural Product Communications, 2012, 7, 1287-94.	0.2	9
25	Comparison of Spray Freeze Drying and the Solvent Evaporation Method for Preparing Solid Dispersions of Baicalein with Pluronic F68 to Improve Dissolution and Oral Bioavailability. AAPS PharmSciTech, 2011, 12, 104-113.	1.5	72
26	Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS Class IV compound. International Journal of Pharmaceutics, 2011, 404, 148-158.	2.6	69
27	Processâ€Induced Phase Transformation of Berberine Chloride Hydrates. Journal of Pharmaceutical Sciences, 2010, 99, 1942-1954.	1.6	38
28	Removal of toxic aristolochic acid components from Aristolochia plants by supercritical fluid extraction. Separation and Purification Technology, 2010, 72, 269-274.	3.9	13
29	Caffeine as a photoprotective agent for diminishing phototoxicity. Toxicology and Industrial Health, 2010, 26, 667-670.	0.6	7
30	Formulation Development and Bioavailability Evaluation of a Self-Nanoemulsified Drug Delivery System of Oleanolic Acid. AAPS PharmSciTech, 2009, 10, 172-182.	1.5	155
31	Influence of Operating Temperature and Pressure on the Polymorphic Transition of Salmeterol Xinafoate in Supercritical Fluids. Journal of Pharmaceutical Sciences, 2008, 97, 1025-1029.	1.6	8
32	Engineering of Pharmaceutical Materials: An Industrial Perspective. Journal of Pharmaceutical Sciences, 2008, 97, 2855-2877.	1.6	114
33	Physical characterization of oleanolic acid nonsolvate and solvates prepared by solvent recrystallization. International Journal of Pharmaceutics, 2008, 355, 195-202.	2.6	29
34	Anti-hygroscopic effect of dextrans in herbal formulations. International Journal of Pharmaceutics, 2008, 363, 99-105.	2.6	27
35	Structure and Drug Release in a Crosslinked Poly(Ethylene Oxide) Hydrogel. Journal of Pharmaceutical Sciences, 2007, 96, 1320-1330.	1.6	14
36	Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications. Pharmaceutical Research, 2007, 24, 203-227.	1.7	392

#	Article	IF	Citations
37	Particle Engineering for Pulmonary Drug Delivery. Pharmaceutical Research, 2007, 24, 411-437.	1.7	560
38	Control of Physical Forms of Drug Particles for Pulmonary Delivery by Spray Drying and Supercritical Fluid Processing. KONA Powder and Particle Journal, 2006, 24, 27-40.	0.9	17
39	Predicting the aerosol performance of dry powder inhalation formulations by interparticulate interaction analysis using inverse gas chromatography. Journal of Pharmaceutical Sciences, 2006, 95, 228-233.	1.6	45
40	Effect of ingesting cranberry juice on bacterial growth in urine. American Journal of Health-System Pharmacy, 2006, 63, 1417-1419.	0.5	13
41	An improved thermoanalytical approach to quantifying trace levels of polymorphic impurity in drug powders. International Journal of Pharmaceutics, 2005, 295, 191-199.	2.6	19
42	Surface characterization of salmeterol xinafoate powders by inverse gas chromatography at finite coverage. Journal of Pharmaceutical Sciences, 2005, 94, 695-700.	1.6	11
43	Effect of Amino Acids on the Dispersion of Disodium Cromoglycate Powders. Journal of Pharmaceutical Sciences, 2005, 94, 2289-2300.	1.6	148
44	Stability of extemporaneous oral ribavirin liquid preparation. International Journal of Pharmaceutical Compounding, 2004, 8, 486-8.	0.0	1
45	Thermal analysis of trace levels of polymorphic impurity in salmeterol xinafoate samples. Pharmaceutical Research, 2003, 20, 1423-1429.	1.7	30
46	Aerosolisation behaviour of micronised and supercritically-processed powders. Journal of Aerosol Science, 2003, 34, 553-568.	1.8	78
47	Physical Properties of Supercritically-Processed and Micronised Powders for Respiratory Drug Delivery. KONA Powder and Particle Journal, 2002, 20, 178-187.	0.9	21
48	Influence of polymorphism on the surface energetics of salmeterol xinafoate crystallized from supercritical fluids. Pharmaceutical Research, 2002, 19, 640-648.	1.7	36
49	Characterization of two polymorphs of salmeterol xinafoate crystallized from supercritical fluids. Pharmaceutical Research, 2001, 18, 852-858.	1.7	84
50	Parameters affecting in-liquid drying microencapsulation and release rate of cefaclor. International Journal of Pharmaceutics, 1998, 172, 113-125.	2.6	13
51	Stability Assessment and Formulation Characterization. , 0, , 371-416.		2